Biomarker in Cisplatin-Based Chemotherapy for Urinary Bladder Cancer

被引：7
作者：
Ecke, Thorsten H. [1 ]
机构：
[1] HELIOS Hosp, Dept Urol, Pieskower Str 33, D-15526 Bad Saarow Pieskow, Germany
来源：
ADVANCES IN CANCER BIOMARKERS: FROM BIOCHEMISTRY TO CLINIC FOR A CRITICAL REVISION | 2015年 / 867卷
关键词：
Adjuvant chemotherapy; Bax; Bcl-2; Biomarker; Bladder cancer; CD40; Chemotherapy; Cisplatin; C-reactive protein (CRP); Emmprin; ERCC1; HER2/neu; Human epidermal growth factor receptor 2 (HER-2); Ki-67; MDR1; Metallothionein (MT); p53; Smac/DIABLO; Survivin; Tissue polypeptide antigen (TPA); TLX3; gene; Transcription factor TFAP2 alpha; TRANSITIONAL-CELL-CARCINOMA; GROWTH-FACTOR RECEPTOR; TISSUE POLYPEPTIDE ANTIGEN; MESSENGER-RNA EXPRESSION; METASTATIC UROTHELIAL CARCINOMA; PROVIDE PROGNOSTIC INFORMATION; TYROSINE KINASE INHIBITORS; LONG-TERM SURVIVAL; NEOADJUVANT CHEMOTHERAPY; ADJUVANT CHEMOTHERAPY;
D O I：
10.1007/978-94-017-7215-0_18
中图分类号：
Q5 [生物化学]; Q7 [分子生物学];
学科分类号：
071010 ; 081704 ;
摘要：
The treatment of metastasized bladder cancer has been evolving during recent years. Cisplatin based chemotherapy combinations are still gold standard in the treatment of advanced and metastasized bladder cancer. But new therapies are approaching. Based to this fact biological markers will become more important for decisions in bladder cancer treatment. A systematic MEDLINE search of the key words "cisplatin", "bladder cancer", "DNA marker", "protein marker", "methylation biomarker", "predictive marker", "prognostic marker" has been made. This review aims to highlight the most relevant clinical and experimental studies investigating markers for metastasized transitional carcinoma of the urothelium treated by cisplatin based regimens.
引用
收藏
页码：293 / 316
页数：24
相关论文
共 141 条
[1]  
Abol-Enein H, 2003, LANCET, V361, P1927
[2]   Survivin: Role in diagnosis, prognosis, and treatment of bladder cancer [J].
Akhtar, Mohammed ;
Gallagher, Lisa ;
Rohan, Stephen .
ADVANCES IN ANATOMIC PATHOLOGY, 2006, 13 (03) :122-126
[3]   Emmprin and survivin predict response and survival following cisplatin-containing chemotherapy in patients with advanced bladder cancer [J].
Als, Anne B. ;
Dyrskjot, Lars ;
von der Maase, Hans ;
Koed, Karen ;
Mansilla, Francisco ;
Toldbod, Helle E. ;
Jensen, Jens L. ;
Ulhoi, Benedicte P. ;
Sengelov, Lisa ;
Jensen, Klaus M. E. ;
Orntoft, Torben F. .
CLINICAL CANCER RESEARCH, 2007, 13 (15) :4407-4414
[4]   Management of primary resistance to gemcitabine and cisplatin (G-C) chemotherapy in metastatic bladder cancer with HER2 over-expression [J].
Amsellem-Ouazana, D ;
Beuzeboc, P ;
Peyromaure, M ;
Viellfond, A ;
Zerbib, M ;
Debre, B .
ANNALS OF ONCOLOGY, 2004, 15 (03) :538-538
[5]  
[Anonymous], 1999, Lancet, V354, P533
[6]   Long-term survival in metastatic transitional-cell carcinoma and prognostic factors predicting outcome of therapy [J].
Bajorin, DF ;
Dodd, PM ;
Mazumdar, M ;
Fazzari, M ;
McCaffrey, JA ;
Scher, HI ;
Herr, H ;
Higgins, G ;
Boyle, MG .
JOURNAL OF CLINICAL ONCOLOGY, 1999, 17 (10) :3173-3181
[7]   Phase I safety, pharmacokinetic, and pharmacodynamic trial of ZD1839, a selective oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with five selected solid tumor types [J].
Baselga, J ;
Rischin, D ;
Ranson, M ;
Calvert, H ;
Raymond, E ;
Kieback, DG ;
Kaye, SB ;
Gianni, L ;
Harris, A ;
Bjork, T ;
Averbuch, SD ;
Feyereislova, A ;
Swaisland, H ;
Rojo, F ;
Albanell, J .
JOURNAL OF CLINICAL ONCOLOGY, 2002, 20 (21) :4292-4302
[8]   Gene expression of ERCC1 as a novel prognostic marker in advanced bladder cancer patients receiving cisplatin-based chemotherapy [J].
Bellmunt, J. ;
Paz-Ares, L. ;
Cuello, M. ;
Cecere, F. L. ;
Albiol, S. ;
Guillem, V. ;
Gallardo, E. ;
Carles, J. ;
Mendez, P. ;
de la Cruz, J. J. ;
Taron, M. ;
Rosell, R. ;
Baselga, J. .
ANNALS OF ONCOLOGY, 2007, 18 (03) :522-528
[9]   Pretreatment prognostic factors for survival in patients with advanced urothelial tumors treated in a phase I/II trial with paclitaxel, cisplatin, and gemcitabine [J].
Bellmunt, J ;
Albanell, J ;
Paz-Ares, L ;
Climent, MA ;
González-Larriba, JL ;
Carles, J ;
de la Cruz, JJ ;
Guillem, V ;
Díaz-Rubio, E ;
Cortés-Funes, H ;
Baselga, J .
CANCER, 2002, 95 (04) :751-757
[10]   Phase I-II study of paclitaxel, cisplatin, and gemcitabine in advanced transitional-cell carcinoma of the urothelium [J].
Bellmunt, J ;
Guillem, V ;
Paz-Ares, L ;
González-Larriba, JL ;
Carles, J ;
Batiste-Alentorn, E ;
Sáenz, A ;
López-Brea, M ;
Font, A ;
Nogué, M ;
Bastús, R ;
Climent, MA ;
de la Cruz, JJ ;
Albanell, J ;
Banús, JM ;
Gallardo, E ;
Diaz-Rubio, E ;
Cortés-Funes, H ;
Baselga, J .
JOURNAL OF CLINICAL ONCOLOGY, 2000, 18 (18) :3247-3255
12345678910